Strategic Collaborations ISA has a proven track record of partnering with Regeneron to advance ISA101, an HPV16 immunotherapy, in combination with PD-1 therapy. This demonstrates openness to large pharma collaborations and suggests opportunities for new alliances around HPV related cancers and other immuno oncology indications.

Proprietary Platform ISA's SLP immunotherapy platform and AMPLIVANT technology offer a differentiated asset that could be marketed through licensing or partnered development to complement oncology portfolios and enable combination strategies in cervical cancer and rare HPV related diseases.

Funding Momentum Financing momentum includes a EUR 26 million round in 2021 with Invest NL and Regeneron, signaling strong investor interest and downstream potential. The capital can underpin expanded clinical activity, manufacturing readiness, and milestone driven partnerships with larger biotech or pharma players.

HPV Pipeline Momentum ISA101 targets HPV related diseases and the company is progressing clinical programs in advanced cervical cancer, HPV16 positive tumors, and anal intraepithelial neoplasia, with proof of concept in vulvar intraepithelial neoplasia. These activities create multiple collaboration angles for co development, licensing, or strategic partnerships around HPV therapies.

EU Partnerships Based in Leiden with a small team, ISA can leverage regional partnerships, EU licensing, or contract development and manufacturing arrangements to scale its SLP platform and bring its immunotherapies to broader patient populations through partner channels.